News

Partnership pairs GMP-manufactured iPSC lines with matched research-grade equivalents, giving developers well-characterized, donor-eligible starting materials from early research through clinical development. Supporting comparability data to be presented at the 2026 ISSCR Annual Meeting in Montreal.   VANCOUVER, BRITISH COLUMBIA, AND TORONTO, ONTARIO, July 8, 2026 – STEMCELL Technologies and the Centre for Commercialization of Regenerative […]

HAMILTON & TORONTO ONTARIO – December 23, 2025 – OmniaBio Inc., Canada’s largest cell and gene therapy (CGT) contract development and manufacturing organization (CDMO), today announced that Health Canada has awarded the company a Drug Establishment License (DEL), confirming the maturity and compliance of its Good Manufacturing Practices (GMP).    Secured less than one year after opening the Hamilton,

TORONTO, ONTARIO & BOSTON, MA – October 1st, 2025 – OmniaBio Inc., a next generation contract development and manufacturing organization (CDMO) pioneering the manufacturing of cell and gene therapies (CGT) with robotics and artificial intelligence, and BrainChild Bio Inc, a clinical-stage biotechnology company developing Chimeric Antigen Receptor T-cell (CAR-T) therapies to treat solid tumors in